Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

LyondellBasell logoLyondellBasell LYB

LyondellBasell said revenue for Q3 2024 fell $236 million (2%) from Q2, and operating income fell $168 million (17%). The company cited lower demand and lower sales volumes from unplanned downtime in its refining business as factors behind the revenue decline.

10-QQuarterly reportFiled Period of report Summary published (UTC)

Key points

AI summary
  1. LyondellBasell said revenue for Q3 2024 fell $236 million (2%) from Q2, and operating income fell $168 million (17%). The company cited lower demand and lower sales volumes from unplanned downtime in its refining business as factors behind the revenue decline.

  2. The company said I&D segment EBITDA decreased by $477 million (60%) in Q3 2024 from Q2. It cited the absence of the $293 million gain on the sale of the EO&D business, which was not present in Q2, as accounting for 37% of the decline, and lower oxyfuels margins as accounting for 15%. It added that these factors drove the decrease compared with Q3.

  3. The company said it generated $1,904 million in operating cash flow in the first nine months of 2024, which is January–September, invested $1,335 million in capital expenditures and returned $1,400 million to shareholders through dividends and share repurchases.

  4. The company said it had cash and cash equivalents of $2,621 million as of September 30, 2024, total debt of $11,260 million including current maturities, and $4,650 million of unused capacity under its credit facilities.

Key figures

Quarter ended September 30, 2024

Revenue
$10.3B
Operating income
$802M
Net income
$573M
EPS
$1.75

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q3 2024 Revenue and Operating Income Changes

LyondellBasell said revenue for Q3 2024 fell $236 million (2%) from Q2, and operating income fell $168 million (17%). The company cited lower demand and lower sales volumes from unplanned downtime in its refining business as factors behind the revenue decline.

Source · Based on the MD&A text of the filing

I&D Segment EBITDA Decline

The company said I&D segment EBITDA decreased by $477 million (60%) in Q3 2024 from Q2. It cited the absence of the $293 million gain on the sale of the EO&D business, which was not present in Q2, as accounting for 37% of the decline, and lower oxyfuels margins as accounting for 15%. It added that these factors drove the decrease compared with Q3.

Source · Based on the MD&A text of the filing

2024 January–September Cash Flow and Shareholder Returns

The company said it generated $1,904 million in operating cash flow in the first nine months of 2024, which is January–September, invested $1,335 million in capital expenditures and returned $1,400 million to shareholders through dividends and share repurchases.

Source · Based on the MD&A text of the filing

Cash and Liquidity and Debt and Credit Capacity as of September 30, 2024

The company said it had cash and cash equivalents of $2,621 million as of September 30, 2024, total debt of $11,260 million including current maturities, and $4,650 million of unused capacity under its credit facilities.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.